PDL-1 and immune checkpoint inhibitors in endometrial cancer #SGOmtg

Michael J. Birrer, MD of Massachusetts General Hospital discusses PDL-1 and immune checkpoint inhibitors in endometrial cancer at SGO 2016.

Transcription:

And the short answer is not a lot and meet your cancer. Has not been one of the first tumors explored for immunotherapy a really was melanoma and real sal. The second wave is involving ovary and. Other tumors in endometrial is probably closer to the third wave. Suffice it to say PT one is expressed. Our and it’s likely that PPL one will also be expressed. We have no clue whether that’s predictive. For. Response.